Activation of Akt signaling in rat brain by intracerebroventricular injection of ouabain: A rat model for mania

Abstract

Intracerebroventricular (ICV) injection of ouabain, a specific Na-K ATPase inhibitor, induces behavioral changes in rats resembling the manic phenotypes of bipolar disorder. The binding of ouabain to the Na-K ATPase affects signal events in vitro including Akt, a possible molecular target of mood disorders. However, the effects of ouabain on Akt in the brain need further clarification. In this study, we investigated changes in the phosphorylation state of Akt in the rat brain after ICV injection of ouabain. Consistent with our previous report, the locomotor activity of rats within 30 min after ouabain ICV injection changed according to the dose with higher doses of ouabain, 0.5 and 1 mM, inducing significant hyperactivity. In addition, ouabain administration induced a dose-dependent increase in the immunoreactivity of p-Akt (Ser473) in the frontal cortex. striatum, and hippocampus after 30 min, and reached statistical significance with 1 mM of ouabain. Phosphorylation of GSK-3 beta (Ser9), FOX01 (Ser256), and eNOS (Ser1177), which are downstream molecules of Akt, was also increased in a dose-dependent manner within the same brain regions. Moreover, hyperactivity was seen for 8 h after a single 1 mM injection of ouabain and increased phosphorylation of Akt (Ser473), GSK-3 beta, (Ser9), FOX01 (Ser256), and eNOS (Ser1177) was also observed in the cortex, striatum, and hippocampus. Thus, intrabrain injection of ouabain induces activation of Akt signaling accompanied by hyperactivity, suggesting the possible role of Akt in ouabain rat model of mania. (C) 2010 Elsevier Inc. All rights reserved. ; This work was supported by the Korea Science and Engineering Foundation (KOSEF) grant funded by the Korean government (MEST) (No. R01-2008-000-11359-0). ; Jornada LK, 2010, J PSYCHIATR RES, V44, P506, DOI 10.1016/j.jpsychires.2009.11.002 ; Freitas TP, 2010, J NEURAL TRANSM, V117, P149, DOI 10.1007/s00702-009-0337-3 ; Cousins DA, 2009, BIPOLAR DISORD, V11, P787 ; Riegel RE, 2009, NEUROCHEM INT, V55, P491, DOI 10.1016/j.neuint.2009.05.003 ; Hamid H, 2009, PROG NEURO-PSYCHOPH, V33, P1103, DOI 10.1016/j.pnpbp.2009.06.002 ; Schleicher M, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000343 ; Aubry JM, 2009, PSYCHOPHARMACOLOGY, V205, P419, DOI 10.1007/s00213-009-1551-2 ; Pietilainen OPH, 2009, AM J MED GENET B, V150B, P683, DOI 10.1002/ajmg.b.30890 ; Tian J, 2009, J BIOL CHEM, V284, P14921, DOI 10.1074/jbc.M808355200 ; Wada A, 2009, J PHARMACOL SCI, V110, P14, DOI 10.1254/jphs.09R02CR ; Polter A, 2009, BIOL PSYCHIAT, V65, P150, DOI 10.1016/j.biopsych.2008.08.005 ; Krishnan V, 2008, BIOL PSYCHIAT, V64, P691, DOI 10.1016/j.biopsych.2008.06.003 ; Beaulieu JM, 2008, MOL INTERV, V8, P230, DOI 10.1124/mi.8.5.8 ; Kim SH, 2008, PROG NEURO-PSYCHOPH, V32, P1637, DOI 10.1016/j.pnpbp.2008.05.027 ; Perrine SA, 2008, J NEUROCHEM, V107, P570, DOI 10.1111/j.1471-4159.2008.05632.x ; McGinty JF, 2008, J NEUROCHEM, V104, P1440, DOI 10.1111/j.1471-4159.2008.05240.x ; Thiselton DL, 2008, BIOL PSYCHIAT, V63, P449, DOI 10.1016/j.biopsych.2007.06.005 ; Liu LJ, 2007, AM J PHYSIOL-CELL PH, V293, pC1489, DOI 10.1152/ajpcell.00158.2007 ; Khundmiri SJ, 2007, AM J PHYSIOL-CELL PH, V293, pC1171, DOI 10.1152/ajpcell.00535.2006 ; Kulikov A, 2007, BBA-BIOMEMBRANES, V1768, P1691, DOI 10.1016/j.bbamem.2007.04.012 ; Roh MS, 2007, EXP MOL MED, V39, P353 ; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009 ; Seo MS, 2007, INT J NEUROPSYCHOPH, V10, P359, DOI 10.1017/S1461145706006869 ; Nesher M, 2007, LIFE SCI, V80, P2093, DOI 10.1016/j.lfs.2007.03.013 ; Wei Y, 2007, MOL PHARMACOL, V71, P835, DOI 10.1124/mol.106.026351 ; Beaulieu JM, 2007, J NEUROSCI, V27, P881, DOI 10.1523/JNEUROSCI.5074-06.2007 ; Aperia A, 2007, J INTERN MED, V261, P44, DOI 10.1111/j.1365-2796.2006.01745.x ; Williams Jason M, 2007, PLoS Biol, V5, pe274, DOI 10.1371/journal.pbio.0050274 ; Herman L, 2007, NEUROSCI BIOBEHAV R, V31, P874, DOI 10.1016/j.neubiorev.2007.04.001 ; SCHONER W, 2007, AM J PHYSIOL-CELL PH, V293, P509 ; Khundmiri SJ, 2006, AM J PHYSIOL-CELL PH, V291, pC1247, DOI 10.1152/ajpcell.00593.2005 ; Eva A, 2006, BBA-BIOMEMBRANES, V1758, P1809, DOI 10.1016/j.bbamem.2006.09.006 ; El-Mallakh RS, 2006, PROG NEURO-PSYCHOPH, V30, P1261, DOI 10.1016/j.pnpbp.2006.04.003 ; Goldstein I, 2006, BIOL PSYCHIAT, V60, P491, DOI 10.1016/j.biopsych.2005.12.021 ; Reif A, 2006, INT J NEUROPSYCHOPH, V9, P13, DOI 10.1017/S1461145705005560 ; Tian J, 2006, MOL BIOL CELL, V17, P317, DOI 10.1091/mbc.E05-08-0735 ; Kotova O, 2006, CELL MOL BIOL, V52, P48, DOI 10.1170/T760 ; Fayard E, 2005, J CELL SCI, V118, P5675, DOI 10.1242/jcs.02724 ; Ahn YM, 2005, INT J NEUROPSYCHOPH, V8, P607, DOI 10.1017/S1461145705005353 ; Ruggero D, 2005, ONCOGENE, V24, P7426, DOI 10.1038/sj.onc.1209098 ; Xu B, 2005, PLOS MED, V2, P999, DOI 10.1371/journal.pmed.0020263 ; Yuan ZK, 2005, MOL BIOL CELL, V16, P4034, DOI 10.1091/mbc.E05-04-0295 ; Vogt PK, 2005, CELL CYCLE, V4, P908, DOI 10.4161/cc.4.7.1796 ; Parsa AT, 2004, TRENDS MOL MED, V10, P607, DOI 10.1016/j.molmed.2004.10.009 ; Reif A, 2004, EUR J NEUROSCI, V20, P885, DOI 10.1111/j.1460-9568.2004.03559.x ; Sessa WC, 2004, J CELL SCI, V117, P2427, DOI 10.1242/jcs.01165 ; Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0 ; Yanik M, 2004, EUR ARCH PSY CLIN N, V254, P43, DOI 10.1007/s00406-004-0453-x ; Kang UG, 2004, PROG NEURO-PSYCHOPH, V28, P41, DOI 10.1016/S0278-5846(03)00173-8 ; El-Mallakh RS, 2003, BIPOLAR DISORD, V5, P362, DOI 10.1034/j.1399-5618.2003.00053.x ; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026 ; Toyota T, 2003, NEUROSCI LETT, V339, P5, DOI 10.1016/S0304-3940(02)01428-3 ; Xie Zijian, 2003, Mol Interv, V3, P157, DOI 10.1124/mi.3.3.157 ; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200 ; De Sarno P, 2002, NEUROPHARMACOLOGY, V43, P1158, DOI 10.1016/S0028-3908(02)00215-0 ; Sutton G, 2002, J NEUROCHEM, V82, P1097, DOI 10.1046/j.1471-4159.2002.01031.x ; Grimes CA, 2001, J NEUROCHEM, V78, P1219, DOI 10.1046/j.1471-4159.2001.00495.x ; Zhou XM, 2001, BIOCHEM BIOPH RES CO, V285, P46, DOI 10.1006/bbrc.2001.5126 ; Snyder SH, 2000, AM J PSYCHIAT, V157, P1738, DOI 10.1176/appi.ajp.157.11.1738 ; Haas M, 2000, J BIOL CHEM, V275, P27832 ; Traub Noam, 2000, Journal of Basic and Clinical Physiology and Pharmacology, V11, P375 ; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159 ; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836 ; Grider G, 1999, J AFFECT DISORDERS, V54, P261, DOI 10.1016/S0165-0327(98)00208-0 ; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745 ; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179 ; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741 ; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4 ; Rose AM, 1998, BIOL PSYCHIAT, V44, P892, DOI 10.1016/S0006-3223(97)00440-X ; Ruktanonchai DJ, 1998, PHYSIOL BEHAV, V63, P403, DOI 10.1016/S0031-9384(97)00457-5 ; Paxinos G, 1998, RAT BRAIN STEREOTACT ; Emamghoreishi M, 1997, AM J PSYCHIAT, V154, P976 ; Li R, 1997, MOL CHEM NEUROPATHOL, V31, P65, DOI 10.1007/BF02815161 ; Looney S W, 1997, Depress Anxiety, V5, P53, DOI 10.1002/(SICI)1520-6394(1997)5:23.0.CO ; 2-6 ; ELMALLAKH RS, 1995, PROG NEURO-PSYCHOPH, V19, P955, DOI 10.1016/0278-5846(95)00123-D ; BREDT DS, 1994, NEURON, V13, P301, DOI 10.1016/0896-6273(94)90348-4 ; ROSKAMS AJ, 1994, NEURON, V13, P289 ; CHRISTO PJ, 1993, MED HYPOTHESES, V41, P378, DOI 10.1016/0306-9877(93)90089-9 ; DUBOVSKY SL, 1992, AM J PSYCHIAT, V149, P118 ; DUBOVSKY SL, 1991, BIOL PSYCHIAT, V29, P441, DOI 10.1016/0006-3223(91)90266-O ; DUBOVSKY SL, 1989, ARCH GEN PSYCHIAT, V46, P632 ; NAYLOR GJ, 1971, BRIT J PSYCHIAT, V118, P219, DOI 10.1192/bjp.118.543.219 ; NAYLOR GJ, 1970, J PSYCHOSOM RES, V14, P173, DOI 10.1016/0022-3999(70)90027-9 ; 5